Jiangsu Hansoh Pharmaceutical Group Co., Ltd. company information, Employees & Contact Information

China's Hansoh signs up to $1.45 billion deal for colorectal cancer drug with Roche Reuters

Licensing galore: Roche ties up with Hansoh on ADCs as Rani rounds out week with Chugai pact Fierce Biotech

Roche Inks Another China ADC Pact With $1.5B Hansoh Bet BioSpace

Hansoh Pharmaceutical Group (SEHK:3692) Valuation: Is Recent Momentum Supported by the Fundamentals? Yahoo Finance

GSK hatches pivotal Hansoh conjugate plans | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Hansoh, Puruixin, VisionBio, Ascletis, Haihe… recently closed five BD deals, further heating up the trend of China’s innovative drug exports! 富途牛牛

Chinese pharma firms Hengrui, Hansoh expected to post strong first-half profits South China Morning Post

Hansoh Pharmaceutical Group Company Limited Just Beat Revenue Estimates By 13% simplywall.st

Merck moves into obesity with deal for Hansoh’s GLP-1 pill BioPharma Dive

GSK and Hansoh press on despite Pfizer’s exit | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Regeneron pens $2B pact for Hansoh's potential obesity rival to Lilly's Zepbound Fierce Biotech

GSK enters exclusive license agreement with Hansoh for HS-20093 GSK

Another milestone for innovative drug exports! Hansoh Pharma signs licensing agreement with Roche for colorectal cancer drug, valued at up to $1.45 billion. 富途牛牛

Hansoh Pharma in HK$3.9 Billion Share Placement Cleary Gottlieb

Merck to develop weight loss pill from Chinese drugmaker in up to $2 billion licensing deal CNBC

Antengene Enters into Commercialization Partnership with Hansoh Pharma for First/Only-in-Class XPO1 Inhibitor XPOVIO®(selinexor) in the Mainland of China PR Newswire

GSK enters exclusive license agreement with Hansoh for HS-20089 GSK

Silence slows phase 3 plans for cardio drug, as Hansoh opts out of $1.3B biobucks collab Fierce Biotech

Merck & Co. boosts GLP-1 portfolio by paying $112M upfront for Hansoh's preclinical drug Fierce Biotech

ESMO: GSK says 'stay tuned' for more ADC data after partner Hansoh posts 49% response rate Fierce Biotech

Hansoh Pharma patent develops CFB inhibitors BioWorld MedTech

Hansoh Pharma discloses new c-KIT inhibitors BioWorld MedTech

Merck Joins Obesity Pill Race With Up to $2B Hansoh Deal BioSpace

Hansoh describes new GLP-1R agonists BioWorld MedTech

Hansoh, fresh from Big Pharma deal table, signs $690M ADC pact with Biotheus Fierce Biotech

Regeneron gains rights to Hansoh’s GLP-1/GIP receptor agonist in deal worth $2bn PMLiVE

Merck strikes a $2B GLP-1 deal with Hansoh BioWorld MedTech

GSK secures another ex-China ADC deal with Hansoh Pharma with $185M upfront Endpoints News

GSK Inks Potential $1.7B ADC Deal with China’s Hansoh Pharma BioSpace

GSK heads back to Hansoh, paying $185M upfront for another ADC Fierce Biotech

Regeneron boosts obesity pipeline with Hansoh’s GLP-1/GIP for $2B BioWorld MedTech

Hansoh Pharma and NiKang Therapeutics Enter into a Development and Commercialization Partnership for a Novel Treatment for Anti-Viral Diseases in China Business Wire

Hansoh scientists patent new HER3-targeting ADCs BioWorld MedTech

NiKang Therapeutics and Hansoh Pharma Announce Strategic Collaboration and License Agreement for NKT2152 in Greater China Business Wire

Terns Pharmaceuticals and Hansoh Pharma Announce Collaboration and License Agreement for TRN-000632 in Greater China Business Wire

Hang Seng review shines light on China’s 6th richest woman at Hansoh Pharma South China Morning Post

Hansoh Pharma and OliX Pharmaceuticals Enter into Licensing GlobeNewswire

Viela Bio, China's Hansoh pen development pact potentially worth $220M-plus Fierce Biotech

Atomwise, Hansoh Pharma Enter Into Up-to-$1.5B AI-Based Drug Discovery Partnership Genetic Engineering and Biotechnology News

GSK inks $85 M deal with China's Hansoh Pharma BioSpectrum Asia

MSD enters into license agreement with Hansoh Pharma for investigational Oral GLP-1 receptor agonist Indian Pharma Post

FiercePharmaAsia—Hansoh-Hengrui billionaire family; Samsung executive's grilling; Aurobindo plant Fierce Pharma

China’s Jiangsu Hansoh Pharmaceutical Plans up to $3 Billion Hong Kong IPO The Wall Street Journal

Hansoh Pharmaceutical to raise nearly HK$4 billion through share sale, Bloomberg says The Standard (HK)